Reni Benjamin analyst JMP

Currently out of the existing stock ratings of Reni Benjamin, 255 are a BUY (87.03%), 38 are a HOLD (12.97%).

Reni Benjamin

Work Performance Price Targets & Ratings Chart

Analyst Reni Benjamin, currently employed at JMP, carries an average stock price target met ratio of 47.12% that have a potential upside of 50.48% achieved within 288 days. Previously, Reni Benjamin worked at RAYMOND JAMES, HC WAINWRIGHT.

Reni Benjamin’s has documented 530 price targets and ratings displayed on 45 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CMPX, Compass Therapeutics at 23-Sep-2026.

Wall Street Analyst Reni Benjamin

Analyst best performing recommendations are on IOVA (IOVANCE BIOTHERAPEUTICS).
The best stock recommendation documented was for IOVA (IOVANCE BIOTHERAPEUTICS) at 3/3/2026. The price target of $5 was fulfilled within 3 days with a profit of $1.25 (33.33%) receiving and performance score of 111.11.

Average potential price target upside

BCYC Bicycle Therapeutics Ltd BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC EFTR Effector Therapeutics INBX Inhibrx INCY yte IOVA Iovance Biotherapeutics SGEN Seagen STRO Sutro Biopharma VYGR Voyager Therapeutics ALLO Allogene Therapeutics CGEN Compugen KURA Kura Oncology ACET Adicet Bio CTIC CTi Biopharma Corp RGNX Regenxbio ADAP Adaptimmune Therapeutics Plc ADVM Adverum Biotechnologies BCAB Bioatla CUE Cue Biopharma SPPI Spectrum Pharmaceuticals URGN UroGen Pharma Ltd AMAM Ambrx Biopharma American Depositary Shares LVTX LAVA Therapeutics NV SANA Sana Biotechnology VSTM Verastem HOWL Werewolf Therapeutics PRLD Prelude Therapeutics AKBA Akebia Ther IDRA Idera Pharmaceuticals SMMT Summit Therapeutics PLC TIL Instil Bio ADMA ADMA Biologics BMRN Biomarin Pharmaceutical BTX Brooklyn Immunotherapeutics NXTC NextCure SG Sweetgreen TRIL Trillium Therapeutics BCAX Bicara Therapeutics Common Stock CMPX Compass Therapeutics LYEL Lyell Immunopharma ZYME Zymeworks Common Stock CNST Constellation Pharmaceuticals IMMP Immutep Ltd ADR ONCE Spark Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 02-Mar-2022

$14

$10.62 (314.20%)

$15

2 months 3 days ago
(30-Jul-2026)

0/24 (0%)

$9.99 (249.13%)

Hold Since 15-Feb-2022

$12

$7.9 (192.68%)

5 months 25 days ago
(08-Apr-2026)

0/8 (0%)

$7.02 (140.96%)

Buy Since 12-Jun-2020

$36

$32.62 (965.09%)

$36

6 months ago
(03-Apr-2026)

3/11 (27.27%)

$30.95 (612.87%)

192

Hold Since 18-Mar-2026

$7

$2.9 (70.73%)

6 months 15 days ago
(18-Mar-2026)

0/3 (0%)

$2.3 (48.94%)

Hold Since 24-Nov-2025

$10

$5.9 (143.90%)

$25

10 months 9 days ago
(24-Nov-2025)

0/5 (0%)

$3.26 (48.37%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Reni Benjamin most bullish on?

Potential upside of $24.74 has been obtained for LYEL (LYELL IMMUNOPHARMA)

Which stock is Reni Benjamin most reserved on?

Potential downside of -$6.22 has been obtained for IOVA (IOVANCE BIOTHERAPEUTICS)

What Year was the first public recommendation made by Reni Benjamin?

On 2015
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?